| The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 20809236 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease (CVD) morbidity and mortality worldwide. Renin-angiotensin system (RAS) blockers have been indispensable in diminishing the macrovascular and microvascular complications of diabetes. In addition, cumulative evidence from retrospective studies pointed toward a beneficial effect of RAS agents in preventing the development and progression of T2DM. This disease-modifying potential of RAS blockers has been substantiated by recent prospective trials. Contemporary concepts regarding the natural history of T2DM and the pathophysiologic processes involved have increased our understanding of the mechanisms underlying the therapeutic potential of these agents in diabetes management. In addition to their established roles in the primary prevention of CVD in patients with diabetes, RAS blockers might be considered a suitable therapeutic choice for preventing the development of frank diabetes in high-risk patients. |
| | |
Authors:
|
Joel A Lardizabal; Prakash C Deedwania |
Related Documents
:
|
18305466 - Free p-cresol is associated with cardiovascular disease in hemodialysis patients. 16164876 - Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. 21076956 - External validation of the uk prospective diabetes study (ukpds) risk engine in patient... 20703436 - The role of diet and lifestyle in primary, secondary, and tertiary diabetes prevention:... 2583926 - The association of lifetime weight and weight control patterns with diabetes among men ... 956746 - Comparative postmortem chemistries of vitreous humor before and after embalming. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current cardiology reports Volume: 12 ISSN: 1534-3170 ISO Abbreviation: Curr Cardiol Rep Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-09-15 Completed Date: 2010-12-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100888969 Medline TA: Curr Cardiol Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 464-71 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of California in San Francisco (Fresno-MEP), 155 North Fresno Street, Fresno, CA 93701, USA. dr_jolar@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II Type 1 Receptor Blockers
/
pharmacology,
therapeutic use* Angiotensin-Converting Enzyme Inhibitors / pharmacology, therapeutic use* Antihypertensive Agents / therapeutic use Blood Glucose / metabolism Cardiovascular Diseases / drug therapy*, etiology, prevention & control Diabetes Mellitus, Type 2 / drug therapy, etiology, prevention & control* Diabetic Angiopathies / prevention & control* Disease Progression Humans Insulin Resistance Microvessels Renin-Angiotensin System / drug effects* Risk Factors Signal Transduction |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Blood Glucose |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The omega-3 index: clinical utility for therapeutic intervention.
Next Document: Effects of the compounds MV8608 and MV8612 obtained from Mandevilla velutina in the model of hemorrh...